Strategic partner
Ethicon (Johnson & Johnson LLC)

Ethicon, a division of Johnson & Johnson Corporation, for more than 80 years is one of the world leaders in the development and production of modern high-tech equipment for minimally invasive and open surgical procedures.

Product portfolio of the company is represented by the following key areas:

  • Modern sutures (more than 1000 SKUs for any area of surgery)
  • Broad portfolio of advanced energy products, including the Harmonic ultrasound scalpel and EnSeal bipolar instruments
  • Modern surgical staplers for open and laparoscopic surgery
  • Absorbable Hemostats
  • Instruments for ligation
  • High-tech solutions for hernia repair
  • Dermal adhesives and drains
  • Tools for endoscopic access

Ethicon products and technologies are widely used in oncology procedures, colorectal and thoracic surgery, cardio- and neurosurgery, pediatric surgery, plastic surgery, , urology, gynecology, and many other specialties.

The main characteristics of the instruments are reliability in the performance, maximum efficiency and ergonomics, reduction in the number of complications. Ethicon produces a wide range of products, which is developed on the basis of the philosophy of Science of Tissue Management, that is, minimally traumatizing the patient's tissues during surgery for the most rapid recovery and return to a high quality of life.

BIOCAD

BIOCAD is one of the largest international innovative biotech companies in Russia. It brought together world-class R&D centers, modern pharmaceutical and biotechnological production, and preclinical and clinical trials, compliant with international standards.

Present product portfolio includes 45 medical products, including 10 biological. More than 40 products are now in different development stages. Development of drugs for cancer therapy is one of the priorities of the company.

Trastuzumab, bevacizumab, and rituximab are the drugs, that are most frequently chosen by healthcare systems for therapies of different cancer types. When in 2014 BIOCAD started producing biosimilars, the availability of medical products for patients improved significantly.

The begging of the new era in cancer treatment started with immune-oncology. For immunotherapy of malignant tumors BIOCAD has a whole portfolio of products in different stages of development:

  • Inhibitors of immune response reference points, that aim different targets on programmed cell death pathway: anti PD-1 and anti PD-L1
  • Inhibitor of immune response reference points anti-CTLA-4 (cytoxic T-lymphocyte associated protein 4)
  • New drugs, operating on the level of anti OX40 receptors
  • Vaccines that potentiate the effect of drugs that inhibit immune response reference points
  • CAR-therapy and other latest scientific developments

There are more that 1400 people working in BIOCAD, including more that 650 scientists and researchers. Offices of the company are located in the USA, Brazil, China, India, Vietnam, Egypt, Finland, and other countries.

General partners
Medtronic

As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations and the burden of chronic disease — faced by families and healthcare systems today. But no one can do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes. Founded in 1949 as a medical repair company, we’re now among the world’s largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in nearly 155+ countries.

Join us in our commitment to take healthcare Further, Together. Learn more at Medtronic.com.

Official partners
“Bristol-Myers Squibb” LLC

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis.

The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.

Since 2009, we have delivered 12 new products to patients with serious diseases. Four of these are biologic products, including groundbreaking immunotherapies that use the body’s immune system to fight cancer. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive R&D pipelines in the industry.

What sets us apart as a BioPharma leader is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases. Generating new ideas and thinking differently are at the heart of everything we do – making a difference in the lives of patients.

HETERO

HETERO LABS LTD - the leading supplier of a wide range of pharmaceutical substances and finished pharmaceutical products for treatment of socially important diseases, such as HIV Oncology, AIDS, Hepatitis, Tuberculosis.

The company gives support of social programs in the field of health care and we help people to keep health and quality of life.

The oncologic portfolio of the company makes more than 30 demanded drugs for treatment of a wide range of oncologic diseases since.

Drugs of the company are distinguished by high quality of pharmaceutical substances and the affordable price.

HETERO LABS LTD has more than 300 registration files on drugs on socially important nosologies.

HETERO LABS LTD works on pharmaceutical the market more than 25 years, the philosophy of the company is parted by more than 15 000 employees worldwide, medicinal preparations and pharmaceutical substances of the company provide available treatment and save life of patients in more than 120 countries.

HETERO LABS LTD upholds a reputation of financially stable, large-scale company, the reliable business partner with larger staff and representations worldwide.

LLC Philips

Philips is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries.

AstraZeneka

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in the main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and millions of patients use its innovative medicines worldwide.

Ipsen

Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s vision is to become a leading global biotech company focused on innovation and specialty care. Ipsen’s commitment to oncology is exemplified through its growing portfolio. Ipsen sells 7 drugs in primary care and specialty including aesthetics.

MSD

For over 100 years, MSD (Merck Sharp & Dohme) is one of the leading global biopharmaceutical company. MSD is a trademark of Merck & Co., Inc., headquartered in Kenilworth, New Jersey, USA. MSD portfolio includes products for treatment and prevention of cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola and others.

For more information visit www.msd.ru or www.msd.com.

Sanofi

Sanofi group is one of the global healthcare leaders. All of the company’s activities – medicine development, production and market entry are focused on finding the best solutions for customer’s and patient’s needs.

The company's oncology portfolio is represented in such nosologies as breast and pancreatic cancer - Abraxane; prostate cancer - Jevtana; thyroid cancer - Thyrogen, Caprelsa; colorectal cancer - Zaltrap.

Takeda

Takeda Pharmaceuticals, LLC located in Moscow, is the Russian marketing and sales organization of Takeda Pharmaceutical Company Limited, Osaka, Japan. For more than 20 years company has been striving to bring better health and brighter future for patients in Russia and CIS with more than 1800 employees working in 135 cities all over the region. Takeda is among the Top10 companies on the Russian pharmaceutical market. In 2013 Takeda opened its new state-of-the-art production site in Yaroslavl.

Program partners
Astellas Pharma

Astellas is among the 25 leading pharmaceutical companies in the world. Established in 2005 through the merger of Yamanouchi and Fujisawa, Astellas continues to develop products in urology, transplantology, infection and other therapeutic areas. Astellas International focuses efforts on research and development programs and strives to improve the people’s quality of life around the world.

Special partners
MERCK

Merck is a leading science and technology company in the healthcare, life science and performance materials sectors. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand.

Exclusive partners
Novartis

Novartis Oncology is a leading innovator in cancer research and commercialization, with the goal of transforming cancer care by creating more effective options for patients. With over 10,000 associates in more than 85 countries, we are one of the largest global developers and providers of practice-changing medicines that address the unmet medical needs of people living with cancer and related diseases. We have an unparalleled portfolio of therapies with 22 drugs on the market and more than 25 new molecular entities in development targeting key molecular pathways in cancer biology. We have a strong global footprint that supports research in several parts of the world as well as commercialization in numerous countries.

3D broadcast partner
KARL STORZ GmbH & Co. KG

KARL STORZ company presents the latest visualization technologies on the video system Image 1S - ICG technologies, near infrared detection for evaluation of lymphatic drainage and location of signaling lymph nodes, perfusion in tissues and complexes of high-resolution 3D.

Partners
OLYMPUS MOSCOW LLC

Olympus Europa is the headquarters for the region Europe, Middle East and Africa (EMEA) of the Olympus Corporation, Tokyo. As a worldwide leading manufacturer of optical and digital precision technology, Olympus provides innovative solutions for state-of-the-art medical systems, digital cameras as well as scientific solutions in the fields of microscopy and industrial inspection.

Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

Pfizer

Pfizer is one of the world's leading biopharmaceutical companies. It was founded over 160 years ago with headquarters located in New York (USA). Every year Pfizer’s medications help more than 150 million people to fight their diseases and lead a healthy lifestyle. The diversified portfolio includes both innovative and long-established products: prescription drugs and vaccines, as well as a number of well-known over-the-counter medications for maintaining health.

SonoScape

SonoScape is a global manufacturer of medical equipment. SonoScape Corporation produces ultrasound scanners, flexible video endoscopy systems, electrocardiographs and hematological analyzers.

Thanks to the concept of "Taking care of life through innovation", SonoScape has developed and manufactured high-quality medical equipment that benefits millions of people.

MPA medical partners

Company "M.P.A. medical partners" has 20 year experience in Russian medical market.

We act as an exclusive and official distributor for:

  • Intuitive Surgical - surgical system da Vinci®;
  • BK Ultrasound – specialized ultrasound scanners;
  • Galil - percutaneous tumor cryoablation;
  • Combat BRS - system for the delivery of Hyperthermic Intra-VEsical Chemotherapy;
  • Derma Medical Systems - Video Dermoscopy System "Molemax HD";
  • Delmont Imaging – office hysteroscopy 2.0;
  • Faxitron – specimen radiography systems.
R-Pharm

R-Pharm is a Russian hi-tech pharmaceutical company that is involved in R&D, manufacturing and sales of medicines. R-Pharm operates in 9 countries throughout the world, it has over 60 branches and subsidiaries.

Roche Moscow Ltd.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.ru